L3VLUP
ProSign in

VIR · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

VIRGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • VIR
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterVIRGILD
Q3 20202 holders, $199m25 holders, $14.2bn
Q4 20203 holders, $189m27 holders, $13.4bn
Q1 20213 holders, $302m24 holders, $14.5bn
Q2 20213 holders, $292m18 holders, $14.9bn
Q3 20213 holders, $272m20 holders, $16.4bn
Q4 20214 holders, $375m20 holders, $16.8bn
Q1 20223 holders, $303m28 holders, $13.2bn
Q2 20224 holders, $176m26 holders, $13.6bn
Q3 20224 holders, $111m24 holders, $13.3bn
Q4 20222 holders, $102m32 holders, $21.1bn
Q1 20234 holders, $198m27 holders, $21.8bn
Q2 20235 holders, $189m24 holders, $20.7bn
Q3 20232 holders, $39m24 holders, $20.0bn
Q4 20232 holders, $43m22 holders, $21.5bn
Q1 20243 holders, $44m30 holders, $20.3bn
Q2 20245 holders, $42m28 holders, $18.5bn
Q3 20245 holders, $25m29 holders, $24.2bn
Q4 20244 holders, $14m28 holders, $25.9bn
Q1 20251 holders, $5.1m33 holders, $32.0bn
Q2 20251 holders, $4.0m27 holders, $30.9bn
Q3 2025none listed holders, n.a.23 holders, $29.4bn
Q4 20252 holders, $9.1m25 holders, $34.3bn
Q1 20263 holders, $17m25 holders, $38.5bn
Q2 20263 holders, $73m26 holders, $34.2bn
VIR

Vir Biotechnology Inc

Holders
2
Reported value
$43m
Buyers
1
Sellers
1

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
22
Reported value
$21.5bn
Buyers
10
Sellers
11

Breadth -1 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2023

Among the 23 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only VIR (1)

Baillie Gifford & Co

Only GILD (21)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →